Allergy Therapeutics (LON:AGY) Reaches New 1-Year High at $35.50

Shares of Allergy Therapeutics plc (LON:AGY) hit a new 52-week high during trading on Monday . The company traded as high as GBX 35.50 ($0.46) and last traded at GBX 35.88 ($0.47), with a volume of 224296 shares changing hands. The stock had previously closed at GBX 33.50 ($0.44).

The stock has a market cap of £220.78 million and a P/E ratio of 33.40. The stock’s fifty day moving average price is GBX 29.44 and its 200 day moving average price is GBX 25.25. The company has a current ratio of 4.23, a quick ratio of 3.61 and a debt-to-equity ratio of 20.42.

About Allergy Therapeutics (LON:AGY)

Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics.

Further Reading: What is the price-sales ratio?

Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.